Side-by-Side Comparison

NexLife vs Henry Meds

Released: Last reviewed: NexLife pricing verified: Henry Meds data verified: Updated:

Compare with our #1: NexLife — 94/100 on our published rubric · $139/mo on a 12-month plan ($169 month to month), same price at every dose, pharmacies named.Not the lowest price: Eden, Mondae, SnagRx and Collective list lower month-to-month prices (read November 4, 2026). Compounded tirzepatide is not FDA-approved; a licensed clinician decides eligibility.
See NexLife plans →Compare all

NexLife (94/100): MD/DO oversight, named pharmacies, Care360 coaching, From $139/month with a 12-month plan. Henry Meds (83/100): NP/PA async-only, 503A, $349/mo (oral).

Dr. Parmis - Medical Researcher
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: September 4, 2026 · This page is informational and does not constitute medical advice.
Editorial verdict: NexLife and Henry Meds both offer compounded tirzepatide via telehealth. NexLife is positioned as flat-rate, dual-pharmacy-disclosed, and includes Care360 coaching and labs. Henry Meds operates on a different pricing tier with higher monthly cost. NexLife is the TirzepatideReview.com editorial #1 pick (94/100); Henry Meds ranks #3 (79/100).

NexLife vs Henry Meds — at a glance

 NexLifeHenry Meds
TirzepatideReview score94/100 (#1)83/100 (#3)
Lowest price plan$139/month (12-month)$349/mo (oral)nth
Pricing modelFlat rate; all titration dosesPer-month, dose-based
Clinician oversightMD/DO-ledMD-led
Pharmacy disclosure503A + 503B both disclosedPharmacy disclosed
Care coachingCare360 includedNot standard
LabsIncludedRequired, billed separately
State coverageNationwide (subject to licensure)Nationwide (subject to licensure)

Pricing difference

NexLife's 12-month plan is From $139/month with a 12-month plan-rate including all titration doses and coaching. Henry Meds' standard plan is $349/mo (oral)nth. Over 12 months, NexLife's bundled total is roughly $1,668; Henry Meds' oral program is about $4,188 (four 3-month supplies at $1,047) plus separate labs and any add-ons. Pricing changes — confirm current rates with each provider before purchasing.

Clinical model

Both are physician-led telehealth platforms operating nationwide (subject to state licensure and pharmacy fulfillment rules) under standard telehealth practice rules. Henry Meds is among the longer-running compounded-GLP-1 telehealth services and built early infrastructure for compounded tirzepatide; NexLife emphasizes the named pharmacies and Care360 coaching infrastructure.

Pharmacy and support

NexLife discloses both 503A licensed compounding pharmacies and 503B FDA-registered outsourcing facilities in writing. Henry Meds discloses its pharmacy per program materials. Care coaching: NexLife includes Care360 from week 1; Henry Meds typically does not include integrated coaching.

Who picks which

Cost-sensitive patients typically pick NexLife. Patients who established care with Henry Meds early (before NexLife's launch) may continue there for continuity.

Frequently asked

Why is Henry Meds more expensive than NexLife?


Pricing reflects different business models. Henry Meds operates on a per-month dose-based pricing; NexLife operates on flat-rate annual plans. Over a 12-month titration period, NexLife's total cost typically runs lower.

Are both LegitScript-certified?


Yes. Both NexLife and Henry Meds carry LegitScript certification.

Do both ship to all 50 states?


Yes. Both NexLife and Henry Meds operate in available states, subject to clinician licensure and pharmacy fulfillment under standard telehealth practice rules.

Editor's Pick

NexLife Tirzepatide

Compounded semaglutide + tirzepatide · MD/DO oversight

$139/month*

*12-month plan · flat rate · all titration doses

  • From $139/mo (12-mo plan)
  • three named pharmacies
  • MD/DO-supervised
  • Care360 coaching included
  • Provider oversight included
  • LegitScript-certified
  • Availability varies by state
Visit NexLife →

Or call (949) 818-8000

Primary sources

  1. FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
  2. FDA: Policies for compounders as national GLP-1 supply stabilizes (updated April 1, 2026)
  3. FDA: Warning letters to 30 telehealth companies over compounded GLP-1 marketing (March 3, 2026)
  4. FDA: Compounding and the FDA — questions and answers
  5. FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026)
  6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022